Breaking News

Panasonic Commits to Partner With Tesla on Battery Gigafactory
Tweet TWEET

Johnson & Johnson Innovation Celebrates Life Science Innovation

  Johnson & Johnson Innovation Celebrates Life Science Innovation

  Collaborations Announced Between Regional Innovators and Johnson & Johnson
                             Family of Companies

Business Wire

LONDON -- October 2, 2013

Johnson & Johnson Innovation today announced several new collaborations in the
European region to coincide with a ‘Celebration of Life Science Innovation’
event, hosted by its London Innovation Centre. The event brings together UK
life science leaders and scientists from the Johnson & Johnson Family of
Companies to celebrate promising advances and discuss novel collaboration
models to deliver better healthcare solutions for patients around the world.

Rt Hon David Willetts MP, Minister for Universities and Science, Professor
Dame Sally Davies, Chief Medical Officer for England, and Dr. Paul Stoffels,
Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals at Johnson &
Johnson, discussed strategies for supporting the health and growth of the
innovation ecosystem at the event being held at the recently-opened Johnson &
Johnson Innovation Centre in London.

Science Minister David Willetts said: "The UK has a long tradition in using
collaboration and partnership to spark new ideas and develop new advances in
the life sciences. I am pleased that Johnson & Johnson have recognised that
strength, and chosen London to be one of their world centres for innovation
and collaboration. The UK Government is committed to creating an environment
in which life sciences can thrive in the UK, as outlined in our industrial
strategy. I want to see the sector continue to grow and be at the front of the
global life sciences race."

“Investing in, collaborating with, and providing support to early-stage
companies and entrepreneurs is critical to our overall strategy of advancing
innovation in life science hotspots throughout the world,” said Paul Stoffels,
MD. “This exemplifies our broader R&D approach towards science-led engagement
with external collaborators which we believe will accelerate the development
of new healthcare solutions that bring more years of life and enhanced quality
of life to people around the world.”

The London Innovation Centre is one of Johnson & Johnson Innovation’s four
regional hubs that focus on identifying and accelerating the most promising
early-stage science that will advance the development of new healthcare
solutions. Several new collaborations were announced today across the European
region:

Collaboration with Effimune – Effimune, a biotech company dedicated to the
discovery and development of drugs that regulate the immune system in
autoimmune disease and transplantation, and Janssen Biotech, Inc., one of the
Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a
global option and license agreement. The agreement provides for a
collaboration among Effimune, the Johnson & Johnson Innovation Centre, London,
and the Janssen Immunology Therapeutic Area to focus on the development and
commercialization of FR104, a monoclonal antibody fragment in preclinical
development for the treatment of immune-mediated diseases.

Investment in Merus – Johnson & Johnson Development Corporation (JJDC) has
made an investment in Merus B.V., a private, venture-backed biopharmaceutical
company based in Utrecht, The Netherlands that is building a pipeline of
single-cell derived human bi-specific antibodies for cancer therapy. The
company is developing antibodies that target both solid tumours and blood
tumours and is the lead in a consortium effort to develop bi-specific
antibodies targeting cancer stem cells with the aim of addressing the elusive
problem of recurrent cancer. The investment aligns with the Janssen
Pharmaceutical Companies’ strategic interest in oncology, which focuses on
several tumour types, including prostate, hematologic, lung and colorectal, to
bring the most compelling science to bear in the development of
transformational therapeutic solutions. JJDC is participating in the extension
of Series B funding as part of a syndicate that includes all the original
Series B investors. JJDC is a strategic corporate venture capital fund whose
investors are co-located with scientific teams in the regional innovation
centres to collaborate closely on identifying investment opportunities.

Research Collaborations - Working in collaboration with Janssen
Pharmaceuticals, Inc. and the Crucell Vaccine Institute, the London Innovation
Centre has also facilitated two vaccine research collaborations. Under one
agreement with DCPrime B.V., Janssen will utilize DCPrime’s DCOne™ technology
in feasibility studies for the development of a dendritic cell-based vaccine.
In a second agreement, Crucell will collaborate with CureVac, on the
development of a respiratory vaccine based on CureVac’s RNActive® technology.

“We are delighted to advance a broad range of collaborations based on exciting
early-stage science with the potential to lead to transformative products for
patients,” commented Patrick Verheyen, head of the Johnson & Johnson
Innovation Centre, London. “Connecting innovators with the resources necessary
to advance new products is central to our mission at Johnson & Johnson
Innovation.”

                                     ###

About Johnson & Johnson Innovation

The London Innovation Centre is part of Johnson & Johnson Innovation, a
division of Johnson & Johnson Finance Limited. Johnson & Johnson Innovation
focuses on accelerating early innovation and enhancing opportunities for
collaboration and investment across Johnson & Johnson’s global healthcare
businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs
and emerging companies focused on early-stage opportunities a one-stop access
to science and technology experts who can facilitate collaborations across the
pharmaceutical, medical device and diagnostics and consumer companies of
Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making
capabilities with the flexibility to adapt deal structures to match
early-stage opportunities and establish novel collaborations that speed
development of those innovations to solve unmet needs in patients. For more
information please visit: www.jnjinnovation.com.

About Johnson & Johnson Development Corporation

Johnson & Johnson Development Corporation (JJDC) is the venture capital
subsidiary of Johnson & Johnson, with investment activity in the medical
device, diagnostic, pharmaceutical, and consumer health areas. Our goal is to
create opportunities that meet the strategic needs of our growing operating
affiliates while providing visibility to innovative emerging technology,
businesses and business models. JJDC measures the success of an investment’s
performance not only in financial returns, but also in the viability of
providing strategic growth opportunities for the Johnson & Johnson Family of
Companies. JJDC is interested in opportunities that address significant unmet
medical needs, have clear competitive advantages, IP protection, an executable
clinical and commercialization plan, and are led by experienced management.
JJDC invests in companies across the continuum from early stage seed
investments to the advanced stages of series venture management. Our
investment teams are based predominantly in Johnson & Johnson Innovation’s
four regional centers in Boston, California, London, and Shanghai. For more
information, please visit http://jjdevcorp.com

Forward-looking Statements

This press release contains "forward-looking statements" as defined in the
United States Private Securities Litigation Reform Act of 1995. The reader is
cautioned not to rely on these forward-looking statements. These statements
are based on current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from the expectations and projections of Johnson &
Johnson Finance Limited, Johnson & Johnson Development Corporation, any of the
Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and
uncertainties include, but are not limited to, general industry conditions and
competition; economic factors, such as interest rate and currency exchange
rate fluctuations; technological advances, new products and patents attained
by competitors; challenges inherent in new product development, including
obtaining regulatory approvals; challenges to patents; impact of business
combinations; changes in behavior and spending patterns or financial distress
of purchasers of health care products and services; changes to governmental
laws and regulations and domestic and foreign health care reforms; trends
toward health care cost containment; and increased scrutiny of the health care
industry by government agencies. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &
Johnson’s Annual Report on Form 10-K for the fiscal year ended December 30,
2012. Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
Johnson & Johnson Finance Limited, Johnson & Johnson Development Corporation,
the Janssen Pharmaceutical Companies and Johnson & Johnson do not undertake to
update any forward-looking statements as a result of new information or future
events or developments.

Contact:

Media Contact:
Ellen Rose
erose89@its.jnj.com
+44 (0)7767 267 493
or
Seema Kumar
908-405-1144
skumar10@its.jnj.com
Investors:
Stan Panasewicz
732-524-2524
or
Louise Mehrotra
732-524-6491